InVitro International, Inc. (IVRO)

OTCMKTS · Delayed Price · Currency is USD
0.0818
-0.0005 (-0.61%)
Mar 9, 2026, 3:23 PM EST
Market Cap1.83M -11.6%
Revenue (ttm)811.29K -26.6%
Net Income106.70K +113.9%
EPS0.00 +100.1%
Shares Out22.26M
PE Ratio20.56
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume62,000
Average Volume43,126
Open0.0800
Previous Close0.0823
Day's Range0.0710 - 0.0818
52-Week Range0.0550 - 0.1600
Beta-0.72
RSI42.47
Earnings DateMar 25, 2026

About InVitro International

InVitro International, Inc. develops test kits for non-animal testing applications in the United States and internationally. Its products include Irritection Assay System, an invitro test, which utilizes the change of relevant macromolecules to predict the ocular and dermal irritancy of chemicals, mixtures, and product formulations; and Corrositex, a non-animal test that determines skin corrosivity based on a biomembrane and chemical detection systems. The company also provides customized technology services for Irritection Assay System install... [Read more]

Sector Healthcare
Founded 1985
Employees 16
Stock Exchange OTCMKTS
Ticker Symbol IVRO
Full Company Profile

Financial Performance

In fiscal year 2024, InVitro International's revenue was $811,290, an increase of 2.35% compared to the previous year's $792,628. Earnings were $106,704, an increase of 6770.83%.

Financial Statements